Company: AIP
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001667011-25-000029
Chunk: 255

Company: Arteris, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 255
---
 the basic earnings per share as the effect of potentially dilutive securities would have been antidilutive.The following table summarizes the potentially dilutive securities that were excluded from the calculation of diluted earnings per share because they would be anti-dilutive:As ofJune 30, 2025June 30, 2024Stock options1,850,551 2,285,281 Restricted stock units5,587,907 6,254,930 Restricted common shares issued for business combination234,859 234,859 Shares committed under the 2021 ESPP75,618 83,445 Total7,748,935 8,858,515 

12

5.    INVESTMENTS

The following tables summarize the fair value and amortized cost of the Company’s cash equivalents and available-for-sale securities by major security type (in thousands):As of June 30, 2025Amortized CostUnrealized Gains (Losses)Aggregate Fair ValueAssets: Corporate bonds$18,609 $26 $18,635 U.S. government agency securities13,631 (3)13,628 Money market funds11,845 — 11,845 U.S. treasury securities7,096 — 7,096 Total financial assets$51,181 $23 $51,204 As of December 31, 2024Amortized CostUnrealized GainsAggregate Fair ValueAssets: U.S. government agency securities$18,730 $16 $18,746 U.S. treasury securities11,752 1 11,753 Money market funds10,410 — 10,410 Corporate bonds8,157 5 8,162 Total financial assets$49,049 $22 $49,071 The maturity dates of the Company’s investments are as follows (in thousands):June 30, 2025Less than one year$35,299 1-2 years15,905 Total$51,204 

As of both June 30, 2025 and December 31, 2024, there were no securities in a continuous net unrealized loss position for more than 12 months. As of both June 30, 2025 and December 31, 2024, the unrealized losses for available-for-sale investments were non-credit related and the Company does not intend to sell the investments that were in an unreal